Physician profile
Thomas W Hobby
NPI 1497749733
$1,882.61
in general payments reported to CMS, 2019-2025
24 companies · $88.00 in 2025
The $88.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $121 · 2021: $734 · 2022: $236 · 2023: $176 · 2024: $113 · 2025: $88.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $391.47 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $252.64 | 2020-2024 | Wegovy |
| Pfizer INC. | $221.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $195.36 | 2019-2022 | |
| Dexcom, INC. | $121.00 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $119.84 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $99.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $69.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $65.83 | 2021-2023 | Shingrix, Arexvy |
| Nestle Healthcare Nutrition INC. | $48.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.49 | 2024 | |
| Abbvie INC. | $33.68 | 2021-2023 | |
| Abbott Laboratories | $31.72 | 2021-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $28.69 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $27.98 | 2025 | Watchman Access System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $18.84 | 2025 | Flucelvax, Fluad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.34 | 2022 | |
| Circassia INC. | $17.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.41 | 2019 | |
| Amgen INC. | $15.37 | 2022 | |
| Lundbeck LLC | $13.10 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hobby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.